




Comparing the efficacy of cipagluco­sidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data

Simon Shohet^{*1} , Noemi Hummel², Shuai Fu³ , Ian Keyzor¹ , Alasdair MacCulloch¹, Neil Johnson¹, Jeff Castelli⁴, Ilona Czarny-Ozga⁵, Tahseen Mozaffar⁶ & Howard Thom^{7,8} 

¹Amicus Therapeutics UK Ltd, One Globeside, Fieldhouse Lane, Marlow, SL7 1HZ, UK

²Certara GmbH, Chester Platz 1, 79539, Lörrach, Germany

³Certara, Office 610, South Tower, Hong Kong Plaza, No. 283 Huaihai Road Middle, Huangpu District, Shanghai, China

⁴Amicus Therapeutics, Inc., 47 Hulfish St., Princeton, NJ, 08542, USA

⁵Certara, Instytut Arcana sp. z o.o. 17, Kuklinskiego Street, 30-720, Krakow, Poland

⁶Department of Neurology, University of California, 1001 Health Sciences Road, Irvine, CA 92697-3950, USA

⁷Population Health Sciences, Bristol Medical School, University of Bristol, 1–5 Whiteladies Rd, Bristol, BS8 1NU, UK

⁸Clifton Insight, Bristol, UK

*Author for correspondence: Tel.: +44 1753 910 692; sshohet@amicusrx.com

Aim: Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory function. Until recently, standard of care was enzyme replacement therapy (ERT) with alglucosidase alfa. Second-generation ERTs avalglucosidase alfa (aval) and cipagluco­sidase alfa with miglustat (cipa+mig) are now available. Without head-to-head trials comparing aval with cipa+mig, an indirect treatment comparison is informative and timely for understanding potential clinical differentiation. **Materials & methods:** A systematic literature review was performed to identify relevant studies on cipa+mig and aval. Using patient-level and aggregate published data from randomized controlled trials (RCTs) and phase I/II and open-label extension (OLE) trials, a multi-level network meta-regression was conducted, adjusting for various baseline covariates, including previous ERT duration, to obtain relative effect estimates on 6-minute walk distance (6MWD, meters [m]) and forced vital capacity (FVC, % predicted [pp]). Analyses of two networks were conducted: Network A, including only RCTs, and network B, additionally including single-arm OLE and phase I/II studies. **Results:** Network B (full evidence analysis) showed that cipa+mig was associated with a relative increase in 6MWD (mean difference 28.93 m, 95% credible interval [8.26–50.11 m]; Bayesian probability 99.7%) and FVC (2.88 pp [1.07–4.71 pp]; >99.9%) compared with aval. The comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points. Analysis of network A showed that cipa+mig was associated with a relative decrease in 6MWD (-10.02 m [-23.62 to 4.00 m]; 91.8%) and FVC (-1.45 pp [-3.01 to 0.07 pp]; 96.8%) compared with aval. **Conclusion:** Cipa+mig showed a favorable effect versus aval when all available evidence was used in the analysis.

First draft submitted: 28 March 2024; Accepted for publication: 30 August 2024; Published online: 17 September 2024

Keywords: cipagluco­sidase alfa • indirect treatment comparison • miglustat • Pompe disease

Pompe disease

Pompe disease is a rare disorder caused by a lack or deficiency of the enzyme acid α -glucosidase that hydrolyzes lysosomal glycogen [1]. It is characterized by progressive loss of muscular and respiratory function [2]. Two forms of



Pompe disease exist: fast-progressing infantile-onset Pompe disease, which presents in the first months of life and is often fatal within 1 year of age without treatment, and late-onset Pompe disease (LOPD), which is progressive and can present at variable ages [1,3]. The combined frequency of infantile- and late-onset Pompe disease is estimated as 1 in 23,000 [4].

Treatments for Pompe disease

Pharmacologic treatment for Pompe disease consists of enzyme replacement therapy (ERT) to slow disease progression. ERT with recombinant human acid α -glucosidase (rhGAA) alglucosidase alfa (alglu) was the first approved treatment of LOPD [5]. Recently, advances have been made with the approvals of second-generation ERTs using rhGAA, such as avalglucosidase alfa (aval) [6,7] and cipaglucosidase alfa in combination with the small molecule stabilizer miglustat (cipa+mig) [8–12].

Need for an indirect treatment comparison

No head-to-head trials are currently available comparing aval with cipa+mig in patients with LOPD. Instead, the two novel ERTs have been studied in two pivotal, phase III randomized controlled trials (RCTs): the COMET trial comparing aval ($n = 51$) with alglu ($n = 49$) in ERT-naïve patients [13], and the PROPEL trial comparing cipa+mig ($n = 85$) with alglu ($n = 38$) in primarily ERT-experienced patients with a smaller cohort of ERT-naïve patients (77% ERT experienced, 23% ERT naïve). Therefore, an indirect treatment comparison (ITC) is required to obtain estimates on their relative effect. This comparison may help us to better understand whether eligible patients with LOPD may benefit from one or another treatment, and potentially inform health technology assessment, cost effectiveness and reimbursement decisions.

ITC methods & multi-level network meta-regression (ML-NMR): ensuring populations are comparable

A standard network meta-analysis (NMA) collects aggregate data from multiple studies on multiple treatments in order to produce consistent estimates of relative treatment effects between each pair of treatments in the network [14,15]. It combines direct evidence (from head-to-head RCTs) and indirect evidence (via a common comparator) in a coherent manner from studies that form a connected network of treatment comparisons. Patient populations included in the RCTs forming a network can differ with respect to prognostic factors (i.e., factors that have an influence on the prognosis of the disease or condition) or with respect to effect modifiers (i.e., factors that lead to a differential effect of the intervention). While differences in prognostic factors across the RCTs included in the network should not impact the NMA results due to randomization and control, an imbalance of effect modifiers can lead to biased results [16].

Data from PROPEL and other clinical studies (e.g., ATB200-02 [17], NEO-1/-EXT [18]) suggest previous ERT treatment is a treatment effect modifier. Thus, a standard NMA might not be suitable to study the indirect treatment effect of cipa+mig versus aval, since the two RCTs (PROPEL and COMET) forming the network via the common comparator alglu differ with respect to previous treatment of the respective study populations at baseline.

Anchored population-adjustment indirect comparison methods such as matching-adjusted indirect comparison [16,19] or simulated treatment comparison (STC) [16,20] would allow a comparison to be made between cipa+mig and aval in similar populations, but since the COMET trial included only ERT-naïve patients, results would be similar to an NMA of COMET and the ERT-naïve subgroup from PROPEL.

Single-arm studies, which are common in rare diseases, can contribute valuable evidence on the effect of treatment in the trial population included. Unanchored matching-adjusted indirect comparison or unanchored STC (i.e., not linked via a common comparator) can be performed to derive relative effects adjusted to the comparator trial population, but they are applicable only to the simple pairwise scenario.

Another population-adjustment indirect comparison method, multi-level network meta-regression (ML-NMR) [21], can provide relative effect estimates for any target population of interest, accounting for various treatment effect modifiers such as a mix of ERT-naïve and ERT-experienced patients with LOPD [22,23]. ML-NMR can be applied to any connected network with any mixture of individual patient-level data (IPD) and aggregate data, and is a generalization of network meta-regression, which is usually based on aggregate data only. Single-arm studies can be included into the network by matching them to comparator arms of the existing RCTs [24,25]. ML-NMR is specified as a valid method for population-adjusted ITC by the National Institute for Health and Care Excellence [21,26].

Objective

The aim of this study was to provide relative effect estimates for cipa+mig versus aval for a patient population such as in the PROPEL study (i.e., including both ERT-naïve [23%] and ERT-experienced [77%] patients with LOPD), reflective of the real-world LOPD population, as demonstrated by ongoing registry studies, in which 78–80% of patients have received ERT previously [19,20]. We accomplish this objective through an ML-NMR.

Methods

Systematic literature review

A systematic literature review (SLR) was conducted identifying relevant RCTs and non-RCTs including single-arm phase I/II and open-label extension (OLE) trials in adult patients with LOPD of the following ERTs: alglu, aval and cipa+mig. Development of the search strategy and eligibility criteria for studies were based on the Population, Intervention, Comparator, Outcome, Study design (PICOS[+]) framework, as presented in [Supplementary Table 1](#).

The SLR followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [27], and the search was conducted on 7–15 September 2022, to identify hits that were available until 31 May 2022. An update of the SLR was performed in August 2023 to retrieve additional hits from 31 May 2022 to 31 July 2023.

Search strategy

The search was run through the Ovid SP® platform. A manual clinical trial registries search was conducted to ensure that ongoing studies and completed third-party studies were exhaustively identified. To complement the search for published trials, abstracts published between 2020 and 2023 from key international conferences were searched. In addition, the grey literature sources Google Scholar and Center for Drug Evaluation and Research were searched. Details on the search strategies can be found in [Supplementary Tables 2–16](#).

Study selection

Each of the records identified during the search was assessed for relevance against the PICOS(+) scheme. For the 2022 SLR, double independent record selection was performed. Discrepancies concerning inclusion or exclusion criteria were resolved through reconciliation by a third reviewer. For the 2023 SLR update, a single reviewer selected the records. Records selected during the SLR were then further assessed for eligibility into the ITC.

Data extraction

All data (trial details, patient characteristics, treatments and outcomes) were extracted by one investigator.

Quality assessment

The critical appraisal of all included RCTs was done using the revised Risk Of Bias tool for randomized trials [28], focusing on the primary and key secondary end points, and the quality of included interventional non-RCTs was assessed using the Risk Of Bias In Non-randomized Studies – of Interventions tool (if full-text publications were available) [29].

ML-NMR approach

The ML-NMR method is described in detail in Phillippo *et al.* [21]. In short, an individual-level regression is fitted to IPD studies and a (numeric) integration of this regression is performed over the aggregate data studies. The ‘multinma’ package of the R statistical software provides a Bayesian implementation through the Stan software [30–33]. The Bayesian framework enables informative priors, which reflect a prior belief of the possible values of the pooled relative effect and effects of covariates, to be chosen to alleviate the limitations of small numbers of studies and low sample sizes, a common issue in rare diseases such as Pompe disease.

Matching of single-arm studies

Single-arm phase I/II and OLE trials were included into the network by matching them to a comparator arm of the comparative studies. The choice of the appropriate comparator arm was based on a matching criterion summing the distances between the (aggregate) baseline characteristics of the single-arm trial and the potential comparator arm ([Supplementary Material](#)) [24].

Outcomes

Outcomes assessed were changes from baseline in 6-minute walk distance (6MWD, m) and forced vital capacity (FVC, % predicted). These two outcomes capture the key Pompe disease manifestations of impaired motor and pulmonary function and served as either the primary or key secondary end point in the recent pivotal RCTs for LOPD treatments, COMET and PROPEL. The primary timepoint of assessment was week 52, but outcome values at timepoints other than week 52 were also included in the analysis.

Models

The linear regression models that were part of the ML-NMR aimed to include all baseline covariates that were considered potential treatment effect modifiers affecting the outcomes of interest, if reported in the studies. Literature and review of LOPD RCTs suggested the following baseline covariates: age [2,13,34,35], sex, baseline outcome values [2,13], height, weight [2], previous ERT duration or ERT status [2,36], angiotensin-converting enzyme genotype [37], cross-reactive immunological material status and severity of muscular damage [34]. In addition, the models included the timepoints of visit (weeks) for each study.

Suitable marginal distributions were chosen for the covariates from which to draw the points for numerical integration over aggregate studies ([Supplement Material](#)).

Covariates were included in the model as main effects (prognostic factor) and interacting with treatment (treatment effect modifier). Covariates were estimated for each treatment independently by specifying a separate regression model for each treatment, if data permitted, and for treatment classes with a regression model per treatment class; the latter approach assumed shared effect modifiers for treatments of the same class.

For 6MWD and FVC, mean difference (MD) between treatments with associated 95% credible intervals (CrIs) were calculated. The Bayesian probability that the treatment was superior ($MD > 0$) or inferior ($MD < 0$) to the reference treatment was also derived. These probabilities are the Bayesian equivalent of one-sided p-values. In line with the recommendations of the American Statistical Association [38], no strict threshold for interpreting these Bayesian probabilities was adopted. Instead, the probability itself was reported. Probabilities were interpreted to suggest strong evidence (probability $< 0.1\%$ or $> 99.9\%$), evidence (probability between 0.1% and 5% or between 95% and 99.9%), weak evidence (probability between 5% and 10% or 90% and 95%) and no evidence [39].

Both fixed-effects (FE) and random-effects (RE) ML-NMR models were evaluated. In RE models, an informative prior was chosen for the between-study heterogeneity parameter τ , as recommended by ISPOR (details in [Supplementary Figures 4 & 5](#)) [40,41].

The deviance information criterion (DIC) and the heterogeneity standard deviation τ (the latter for RE models only) were used to assess goodness-of-fit of the models and to select the final model [42]. A decrease of at least 5 points in the DIC of the RE model in comparison with the DIC of the FE model was considered as an indicator of heterogeneity in the network of evidence [43].

Scenarios

A base case scenario was evaluated in which all included covariates were set to the target population of the PROPEL trial (which included a mix of ERT-naïve and ERT-experienced patients with LOPD reflective of the real-world population). To study the impact of covariates on relative effects, the covariate values were varied one by one, keeping the remaining covariate values as in the base case scenario.

Ranking of treatments

The surface under the cumulative ranking curve (SUCRA) is a metric to evaluate which treatment in a network is likely to be the most efficacious [44]. The posterior SUCRA ranking was calculated for each analysis (details in the [Supplement](#)).

Results

SLR results

A total of 1262 records were identified in the specified databases, and a total of 44 publications representing nine studies and three systematic reviews were included in the SLR ([Supplementary Figure 1](#)). A list of included publications can be found in [Supplementary Table 17](#).

Quality assessment of the studies revealed low (for the included RCTs) to moderate (for the included single-arm/extension/observational studies for which full-text publications were available) risk of bias (Supplementary Tables 18 & 19).

Three of the nine studies included in the SLR and their corresponding records were excluded from the ITC: two studies had neither cipa+mig nor aval as an intervention or comparator [5,45] and one study was not an RCT [46]. Also, three systematic reviews were excluded from the ITC [35,47,48]. This resulted in a total of 34 records/six studies included in the ITC (Supplementary Table 17) [2,13,18,49–51]. All included studies were prospectively planned sponsor-initiated studies of high-quality standard.

Trial & patient characteristics

The trial and baseline characteristics of the included studies are shown in Table 1.

In the OLE trials, patients switching to the investigational treatment (aval in COMET OLE, cipa+mig in PROPEL OLE) after the double-blind period were re-baselined in our analysis, and a previous ERT duration of the length of the double-blind period (0.9 years for COMET OLE, 1 additional year for PROPEL OLE) was assigned to them.

The analysis used patient-level data from the PROPEL trial and aggregate-level data from the other five studies.

Efficacy data

Efficacy results of the included studies are shown in Supplementary Table 20, Supplementary Figures 2 & 3.

Networks

Two different networks were considered in this study: a network including only the phase III RCTs PROPEL and COMET, forming a connected network via the common comparator alglu (network A – RCTs only, Figure 1), and a network also including the single-arm and OLE studies for cipa+mig and aval (network B – full evidence, Figure 1).

Matching of single-arm studies

The cipa+mig arms from ATB200-02 and PROPEL OLE were matched to the alglu arm from PROPEL, the aval arm from COMET OLE was matched to the alglu arm from COMET, and the aval arm from NEO-1/-EXT was matched to the alglu arm from PROPEL and, as a sensitivity analysis, to the alglu arm from COMET, since the matching criterion revealed similar results (Supplementary Table 21).

Estimation of covariate effect

The baseline covariates included in the models were age (years), sex (% male), previous ERT duration (years), and 6MWD (m; for analysis of 6MWD) or FVC (% predicted; for analysis of FVC). For the analysis of network A, cipa+mig and aval were grouped into the same treatment class due to limited data from only two RCTs, and the effect of covariates was estimated separately for {cipa+mig, aval} and for {alglu}. For the analysis of network B, the evidence base allowed the effect of covariates to be estimated separately for {cipa+mig}, {aval} and {alglu}, but also the grouping {cipa+mig, aval}, {alglu} was explored.

Model evaluation

Assessment of the ML-NMR models is shown in Table 2, providing the DIC for all models, and the estimated between-study heterogeneity standard deviation τ for RE models.

As can be seen, the between-study standard deviation τ was high in comparison to estimated treatment effects when covariates were estimated for two treatment classes, suggesting more significant between-study heterogeneity. This was confirmed by the improved model fit for 6MWD of the RE model over the FE model (DIC decreased >5 points), but not for FVC (similar DICs).

In contrast, between-study heterogeneity seemed low or accounted for in the models where the covariate effect was estimated separately for the three ERTs: τ was low, and the DICs were similar for both FE and RE models. Based on those considerations, we chose B-FE-3 as the final model to analyze network B for both outcomes.

Table 1. Trial and patient baseline characteristics of included trials.												
Trial name	NCT	Trial design	Follow-up time (weeks)	Population	Intervention	n	Age (years), mean (SD)	Male (%)	ERT duration in years, mean (SD)	6MWD in meters, mean (SD)	FVC (predicted, %), mean (SD)	Ref.
NEO-1/-EXT	NCT01898364/ NCT02032524	Phase I/II, single arm	312	ERT-N	Aval	10	44.8 (20.3)	30.0	0.0 (0.0)	449.2 (118.4)	69.2 (19.3)	[17,55]
COMET	NCT02782741	Phase III RCT	49	ERT-E		14	46.7 (14.1)	64.3	4.0 (2.0) [†]	440.4 (141.0)	77.3 (16.5)	[12]
				ERT-N	Aval	51	46.0 (14.5)	52.9	0.0 (0.0)	399.3 (110.9)	62.5 (14.4)	
COMET OLE	NCT02782741	Phase III OLE	96 [‡]	ERT-E [‡]	Alglu	49	50.3 (13.7)	51.0	0.0 (0.0)	378.1 (116.2)	61.6 (12.4)	[49,56]
ATB200-02	NCT02675465	Phase I/II, single arm	208	ERT-E	Cipa+mig	17	46.4 (11.7) [§]	64.7	7.0 (1.6) [¶]	393.5 (119.7)	57.1 (17.9)	
PROPEL	NCT03729362	Phase III RCT	52	ERT-N	Cipa+mig	6	47.2 (12.0) [#]	16.7	0.0 (0.0)	396.0 (75.2)	57.2 (20.8)	[2]
				ERT-E	Cipa+mig	65	48.1 (12.6) ^{††}	43.1 ^{††}	7.5 (3.4) ^{††}	346.9 (110.2)	67.9 (19.1)	
				ERT-N		20	46.0 (15.3) ^{††}	40.0 ^{††}	0.0 (0.0)	393.6 (112.4)	80.2 (18.7)	
				ERT-E	Alglu ^{‡‡}	30	45.9 (13.5) ^{††}	46.7 ^{††}	7.1 (3.6) ^{††}	334.6 (114.0)	67.5 (21.0)	
PROPEL OLE	NCT04138277	Phase III OLE	52	ERT-N		7	43.0 (13.5) ^{††}	71.4 ^{††}	0.0 (0.0)	420.9 (135.7)	79.1 (22.6)	[50,57]
				ERT-E	Cipa+mig	37	46.0 (12.7) ^{§§}	51.4	6.7 (4.3) ^{††}	359.7 (137.4) ^{††}	62.8 (20.5) ^{††}	
[†] This was derived from the range of 0.9 to 7.9 years provided in Dimachkie <i>et al.</i> 2022 [18], using formulas from Wan <i>et al.</i> 2014 [56] and assuming a median of $(7.9-0.9)/2 = 3.5$.												
[‡] Patients who switched from alglu to aval after the double-blinded primary analysis period in COMET were re-baselined at week 49; therefore, those patients were followed for 96 weeks and considered ERT experienced with a previous ERT duration of the length of the double-blinded primary analysis period (i.e., 49 weeks = 0.9 years).												
[§] This was derived as follows: Median and range of Cohort 1 and 4 provided by Mozaffar <i>et al.</i> 2023 [17] were converted to mean and SD using formulas from Wan <i>et al.</i> 2014 [56]. Then, a weighted mean and pooled SD was calculated to obtain mean and SD of the pooled Cohort 1 and 4.												
[¶] A weighted mean and pooled SD was calculated from mean and SD values for Cohort 1 and 4 provided by Mozaffar <i>et al.</i> 2023 [17] to obtain mean and SD of the pooled Cohort 1 and 4.												
[#] This was derived as follows: Median and range provided in Schoser <i>et al.</i> 2022 [57] were converted to mean and SD using formulas from Wan <i>et al.</i> 2014 [56].												
^{††} From individual patient-level data.												
^{‡‡} Excluding one patient who deliberately underperformed on baseline assessments to meet inclusion criteria as described in Schoser <i>et al.</i> 2021 [2].												
^{§§} This was derived as follows: Median and range were converted to mean and SD using formulas from Wan <i>et al.</i> 2014 [56].												
6MWD: 6-minute walk distance; alglu: Alglucosidase alfa; aval: Avalglucosidase alfa; cipa+mig: cipaglucosidase alfa plus miglustat; ERT: Enzyme replacement therapy; ERT-E: ERT experienced; ERT-N: ERT naive; FVC: Forced vital capacity; OLE: Open-label extension; RCT: Randomized controlled trial; SD: Standard deviation.												




Figure 1. Networks for six-minute walk distance (m) and forced vital capacity (% predicted). Network A: RCTs-only network, network B: full evidence network.

AD: Aggregate data; alglu: Alglucosidase alfa; aval: Avalglucosidase alfa; cipa: Cipaglucosidase alfa; IPD: Individual patient-level data; mig: Miglustat; OLE: Open-label extension.

Table 2. Goodness-of-fit of ML-NMR models.

Model	Network	Treatment classes	Matching	6MWD (m)		FVC (% predicted)	
				DIC	τ [95% CrI]	DIC	τ [95% CrI]
A-FE-2	A	{cipa+mig, aval}, {alglu}	NA	543.0	NA	634.3	NA
B-FE-2	B	{cipa+mig, aval}, {alglu}	aval from NEO-1/-EXT to alglu from PROPEL	642.3	NA	731.7	NA
B-RE-2	B	{cipa+mig, aval}, {alglu}	aval from NEO-1/-EXT to alglu from PROPEL	615.8	12.3 [7.6 to 17.5]	734.9	3.0 [0.0 to 11.9]
B-FE-3	B	{cipa+mig}, {aval}, {alglu}	aval from NEO-1/-EXT to alglu from PROPEL	631.0	NA	715.3	NA
B-RE-3	B	{cipa+mig}, {aval}, {alglu}	aval from NEO-1/-EXT to alglu from PROPEL	631.8	0.3 [0.0 to 2.8]	715.3	0.4 [0.0 to 5.1]
SB-FE-2	B	{cipa+mig, aval}, {alglu}	aval from NEO-1/-EXT to alglu from COMET	637.2	NA	741.3	NA
SB-RE-2	B	{cipa+mig, aval}, {alglu}	aval from NEO-1/-EXT to alglu from COMET	611.8	12.2 [7.3 to 17.4]	736.4	6.4 [0.0 to 14.4]
SB-FE-3	B	{cipa+mig}, {aval}, {alglu}	aval from NEO-1/-EXT to alglu from COMET	630.3	NA	716.0	NA
SB-RE-3	B	{cipa+mig}, {aval}, {alglu}	aval from NEO-1/-EXT to alglu from COMET	632.2	0.4 [0.0 to 4.0]	721.3	0.4 [0.0 to 5.4]

A-FE-2: Analysis of network A (RCTs only) with FE model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}; B-FE-2: Analysis of network B (full evidence) with FE model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}; B-RE-2: Analysis of network B (full evidence) with RE model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}; B-FE-3: Analysis of network B (full evidence) with FE model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}; B-RE-3: Analysis of network B (full evidence) with RE model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}; SB-FE-2: Analysis of network B (full evidence) with FE model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}, with aval from NEO-1/-EXT matched to alglu from COMET; SB-RE-2: Analysis of network B (full evidence) with RE model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}, with aval from NEO-1/-EXT matched to alglu from COMET; SB-FE-3: Analysis of network B (full evidence) with FE model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}, with aval from NEO-1/-EXT matched to alglu from COMET; SB-RE-3: Analysis of network B (full evidence) with RE model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}, with aval from NEO-1/-EXT matched to alglu from COMET.

6MWD: 6-minute walk distance; alglu: Alglucosidase alfa; aval: Avalglucosidase alfa; cipa+mig: cipaglucosidase alfa with miglustat; CrI: Credible interval; DIC: Deviance information criterion; FE: Fixed effect; FVC: Forced vital capacity; NA: Not applicable; RE: Random effect.

Relative effects estimation based on ML-NMR

Base case scenario results

Base case covariate settings were the same as in PROPEL with age = 46.95 years, % male = 45.08, ERT duration = 5.744 years, 6MWD (m) = 355.8, FVC (% predicted) = 70.42, time = 52 weeks.




Figure 2. Forest plots for six-minute walk distance (m) and forced vital capacity (% predicted), base case scenario.
A-FE-2: Analysis of network A (RCTs only) with fixed-effects model and estimating the covariate effect separately for {cip+mig, aval} and {alglu}; B-FE-3: Analysis of network B (full evidence) with fixed-effects model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}.
6MWD: 6-minute walk distance; alglu: Alglucosidase alfa; aval: Avalglucosidase alfa; cipa+mig: Cipaglugosidase alfa plus miglustat; CrI: Credible interval; FVC: Forced vital capacity; MD: Mean difference; RCT: Randomized controlled trial.

Relative effects under the base case scenario at week 52 are shown in [Figure 2](#) for the selected ML-NMR models. The analysis of network A (RCTs only; Model A-FE-2), driven primarily by the subset of matched ERT-naïve patients in the RCT network (PROPEL: 27 ERT-naïve patients), showed that cipa+mig was associated with an increase in 6MWD (m) (MD 14.64 m, 95% CrI [7.07 to 22.31]; Bayesian probability >99.9%) and FVC (% predicted; 2.53 [1.38 to 3.67]; >99.9%) as compared with alglu, with a reduction in 6MWD (-10.02, [-23.62 to 4.00]; 91.8%) and FVC (-1.45 [-3.01 to 0.07]; 96.8%) compared with aval, and aval was associated with an increase in 6MWD (24.66 [9.95 to 39.55]; >99.9%) and FVC (3.98 [2.40 to 5.64]; >99.9%) compared with alglu. The analysis of network B (full evidence; Model B-FE-3) revealed that cipa+mig was associated with an increase in 6MWD and FVC compared with alglu and aval (6MWD: 13.64 [8.73 to 18.70]; >99.9% and 28.93 [8.26 to 50.11]; 99.7%, respectively; FVC: 3.95 [3.23 to 4.69]; >99.9% and 2.88 [1.07 to 4.71]; >99.9%, respectively), and aval was associated with a reduction in 6MWD (-15.30 [-35.33 to 6.43]; 92.8%), but not different in FVC (1.07 [-0.71 to 2.92]; 87.6%) compared with alglu. Results of other models evaluated for network B were directionally consistent with those of Model B-FE-3, with evidence – or strong evidence – of a favorable effect of cipa+mig versus aval for both end points across all models ([Supplementary Figure 4](#)).

Ranking of treatments

The SUCRA scores for 6MWD and FVC for the base case scenario are shown in [Figure 3](#). For the analysis of network A and both end points, the SUCRA score was highest for aval, with the posterior probability of ranking the best close to 1. Cipa+mig had the second-best SUCRA score, with the posterior probability of ranking the best of approximately 0.5. For the analysis of network B (full evidence), cipa+mig always had the highest SUCRA score, with the posterior probability of ranking the best being 1. For 6MWD, the second-best treatment option according to the SUCRA score was alglu, while for FVC it was aval. Results were generally consistent for the other models evaluated ([Supplementary Figure 5](#)).

Impact of covariates on relative effects

Relative effects for different previous ERT durations (previous ERT duration = 0 years [i.e., naïve patients], 2.5 years, 5 years and 9.2 years) are shown in [Supplementary Figure 6](#). The comparison between cipa+mig and alglu became more favorable for cipa+mig with increasing previous ERT duration for both end points in the analysis of both networks.




Figure 3. SUCRA scores, base case scenario.

A-FE-2: Analysis of network A (RCTs only) with fixed-effects model and estimating the covariate effect separately for {cipa+mig, aval} and {alglu}; B-FE-3: Analysis of network B (full evidence) with fixed-effects model and estimating the covariate effect separately for {cipa+mig}, {aval} and {alglu}.

6MWD: 6-minute walking distance; alglu: Alglucosidase alfa; aval: Avalglucosidase alfa; cipa+mig: Cipaglucosidase alfa plus miglustat; FVC: Forced vital capacity; RCT, Randomized controlled trial; SUCRA, Surface under the cumulative ranking curve.

It should be noted that, for Model A-FE-2, the effect of previous ERT duration was canceled out in the comparison between cipa+mig and aval, as the same regression model was estimated for cipa+mig and aval (shared effect modifier). For Model B-FE-3, the comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points, but also the width of the CrIs increased due to less evidence informing those scenarios.

The comparison between aval and alglu became less favorable for aval with increasing previous ERT duration for both end points in the analysis of network B, but when the network A was analyzed, it became more favorable for aval with increasing previous ERT duration. The key driver of this discrepancy was the NEO-1/-EXT trial, where a decrease of 6MWD and FVC was clearly observed with aval at later timepoints.

In addition to previous ERT duration, the impact of time on the relative effects was tested (Supplementary Figure 7). Results regarding the impact of the other baseline variables included in the regression models (i.e., age, sex, 6MWD and FVC) on the relative effect estimates are not shown because none of the covariates was significant.

Discussion

No head-to-head trials are currently available comparing aval and cipa+mig in patients with LOPD. After exploring various indirect comparison methodologies, an ML-NMR was chosen as the most appropriate and robust method to make this comparison. We used patient-level data from PROPEL and publicly available data from other studies on aval and cipa+mig (identified through an SLR) to obtain indirect estimates of relative effects and to evaluate how those treatments rank among each other. End points assessed were 6MWD and FVC changes from baseline

at week 52, which are standard end points in clinical trials in Pompe disease, and are well accepted by clinicians, health technology assessment agencies and payers [58].

Analyses of two networks were conducted: network A, which included only RCTs, and network B, which also included single-arm OLE and phase I/II studies, to enhance the evidence base for the relative effects and, specifically, the effect of aval in ERT-experienced patients.

The results from the analysis of network A under the base case scenario (i.e., covariates set to PROPEL values) provided evidence of a less favorable effect of cipa+mig versus aval for both outcomes (6MWD: weak evidence), with the SUCRA score indicating aval as the most efficacious treatment for both end points, followed by cipa+mig. The results from the analysis of network B provided evidence of a favorable effect of cipa+mig versus aval for both outcomes (FVC: strong evidence) that was further supported by the results of other models explored in the analysis of network B. The SUCRA score indicated cipa+mig as the most efficacious treatment option for both end points, followed by aval (FVC) or alglu (6MWD), that led to a mean increase in 6MWD of 28.93 (8.26 to 50.11) m and in FVC of 2.88 (1.07 to 4.71) pp compared with aval. These results show that the positioning of cipa+mig compared with aval changes to superiority when additional evidence on the effect of aval in patients with LOPD previously treated with ERT is included in the analysis. These additional trial data on aval indicated reduced performance of aval in ERT-experienced patients, which explains why the analysis of network B revealed less favorable results for aval in an ERT-experienced LOPD population, which was the dominant population of the PROPEL trial. Exploring the impact of previous ERT duration revealed that the comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points in the analysis of network B.

We can speculate that the reasons for the observed difference in efficacy between cipa-mig and aval (that is most notable for the patients previously treated with alglu) is most likely due to differences in their chemistry and modes of action, though this is a matter of ongoing debate [52–54]. Cipa is biologically synthesized with high levels of bis-phosphorylated mannose-6-phosphate and retained endolysosomal glycan processing, which, together with the addition of miglustat, may enable more active enzyme into target tissues. For patients who have been undergoing therapy for an extended period of time, cipa+mig may be able to clear accumulated, and more highly complexed, glycogen in skeletal muscles. This would lead to the differentiation seen between enzymes in the results of network B in terms of functional measures of 6MWD and FVC.

To our knowledge, there exists only one other ITC approach comparing cipa+mig and aval. It applied an anchored STC in ERT-naïve and an unanchored STC in ERT-experienced patients with LOPD, using data from COMET and PROPEL (ERT-naïve subgroup only) for the anchored STC and data from COMET OLE, NEO-1/-EXT, PROPEL and ATB200-02 for the unanchored STC [59]. Results of the anchored STC were directionally consistent with the ML-NMR results for network A, but the results of the unanchored STC differed from the ML-NMR results for network B, showing favorable results for aval compared with cipa+mig. This was presumably due to data and analysis limitations such as STC estimates extrapolated from a regression model based on data from few participants (e.g., only 18 patients on aval with previous ERT duration of ≥ 3 years, whereas $>90\%$ of the patients in PROPEL [$n = 61$] had previous ERT duration ≥ 3 years) and assumptions made on baseline characteristics not reported separately for ERT-naïve and -experienced patients in PROPEL.

Our ML-NMR made optimal use of the available data (i.e., individual patient-level data of the PROPEL trial and aggregate data of the other trials included). It is a method recommended by the National Institute for Health and Care Excellence's Decision Support Unit [26].

Limitations

Due to network A being formed only by two studies, the effect of covariates was not estimated separately for cipa+mig and aval, and shared effect modifiers were assumed. Since COMET did not include any ERT-experienced patients, the impact of previous ERT duration on the treatment effect of aval had to be extrapolated from that on cipa+mig where both ERT-naïve and ERT-experienced patients were available, which is a strong assumption.

To overcome this deficiency, network B was analyzed, which included evidence on aval in ERT-experienced patients from single-arm phase I/II and OLE studies. Single-arm trials were matched to an appropriate comparator arm of the head-to-head clinical trials. This can result in biased relative effect estimates when there is still high heterogeneity between the single and the matched arm, despite the optimal choice minimizing the relative differences between the two arms [24,25]. Another limitation of that approach is that evidence of the comparator arms is used

multiple times in the network. Hence, there is a trade-off between a potential bias in the relative effect estimates in the analysis of network B and the improper accounting for previous ERT duration in the analysis of network A.

Another limitation of the ML-NMR method is that it can only adjust the relative effect estimates for any observed effect modifier available in the data, but cannot adjust for unobserved or unobservable effect modifiers. In the present analysis, a significant number of potential treatment effect modifiers were included in the analysis: age, sex, previous ERT duration, time, baseline 6MWD and/or baseline FVC, while others such as weight, height, muscle damage and angiotensin-converting enzyme genotype could not be included due to lack of reporting.

Finally, inconsistency could not be assessed as there were no closed loops in the network.

Conclusion

In the absence of head-to-head trials, the results of this ITC provide clinically important results and inform decision-making on the optimal choice of treatment in patients with LOPD, with cipa+mig being the treatment option with the highest probability of ranking best among all treatments compared when all available evidence was used in the analysis. We suggest that the differences in chemistry and mode of action between cipa+mig and aval can help explain why cipa+mig appears to be more efficacious in the analysis of network B, and why pre-treated patients are more responsive.

The chosen method, ML-NMR, made optimal use of the available evidence, and enabled incorporation of evidence from trials whose included patient populations differed with respect to an important treatment effect modifier, namely previous ERT duration.

Clinical evidence will continue to evolve as longer-term data on the effect of Pompe disease treatments become available. This will allow for more robust, long-term relative effect estimates, as well as insights into modes of action that may better explain the underlying clinical differences.

Summary points

- Both recently approved enzyme replacement therapies (ERTs), cipaglucosidase alfa with miglustat (cipa+mig) and avalglucosidase alfa (aval), show numerical superiority over alglucosidase alfa (alglu) in 6-minute walk distance (6MWD) and forced vital capacity (FVC) in the pivotal trials PROPEL and COMET, but there exist no head-to-head trials comparing cipa+mig and aval directly.
- PROPEL and COMET differ with respect to the included trial population: PROPEL includes 77% of late-onset Pompe disease (LOPD) patients previously treated with ERT, whereas COMET includes 100% ERT-naïve patients.
- Previous ERT duration is considered as an effect modifier for cipa+mig; therefore, a standard network meta-analysis including PROPEL and COMET with their common comparator alglu is not considered appropriate to derive relative effect estimates between the two new ERTs.
- Also, standard population-adjustment methods, such as matching-adjusted indirect comparison and simulated treatment comparison, are not suitable to obtain a relative effect estimate between cipa+mig and aval in the target population of interest, particularly in an LOPD population that includes mainly ERT-experienced patients, such as in PROPEL, since they only adjust for the comparator trial population.
- In this study, an indirect treatment comparison applying a multi-level network meta-regression was conducted, adjusting for previous ERT duration as the effect modifier.
- Two networks were studied: network A, including only the two randomized controlled trials (RCTs) COMET and PROPEL, and network B, additionally including – via matching to comparator arms – single-arm evidence from phase I/II and open-label extension trials that were the only source providing information on the effect of aval in ERT-experienced patients.
- Results from network B adjusted to reflect a real-world LOPD population, such as in PROPEL, revealed that cipa+mig was associated with an increase in 6MWD and FVC at week 52 compared with aval, and that the comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points.
- Analysis of network A showed that cipa+mig was associated with a decrease in 6MWD and FVC at week 52 compared with aval.
- The chosen network of evidence greatly impacts the conclusions drawn about the favorability of one ERT over another, and decision-makers should consider several networks of evidence when evaluating indirect treatment comparison results, rather than the most conservative methods (i.e., networks of RCTs).
- Research should continue as new evidence on cipa+mig and aval for LOPD continues to evolve in the real-world setting.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: <https://bpl-prod.literatumonline.com/doi/10.57264/cer-2024-0045>

Author contributions

Authors A MacCulloch, H Thom, I Czarny-Ozga, I Keyzor, J Castelli, N Hummel, N Johnson, S Fu, S Shohet and T Mozaffar were responsible for study conception and design, data analysis and interpretation and reviewing the draft manuscript for important intellectual content. Authors I Czarny-Ozga, I Keyzor, N Hummel, S Fu and T Mozaffar were responsible for data acquisition. Authors A MacCulloch, H Thom, I Czarny-Ozga, N Thom, N Johnson, S Fu and S Shohet were responsible for drafting the manuscript. Authors A MacCulloch, H Thom, N Hummel and S Fu were responsible for statistical analysis. Author A MacCulloch was responsible for provision of study materials or patients and administrative, technical or logistic support. Authors A MacCulloch and S Shohet were responsible for obtaining funding and supervision.

Acknowledgments

The authors thank the patients, their families and Pompe disease patient organizations as well as the PROPEL study investigators. I Keyzor, formerly of Amicus Therapeutics, Ltd, is currently based at Astellas Pharma Europe Ltd, Addlestone, UK. We would like to thank S Raza for his comments and feedback on this manuscript.

Financial disclosure

This study was supported by Amicus Therapeutics Ltd. S Shohet, A MacCulloch, N Johnson and J Castelli are employees of and hold stock in Amicus Therapeutics, Inc. I Keyzor has previously been an employee of Amicus Therapeutics, Ltd, and holds stock in Amicus Therapeutics, Ltd. I Keyzor is currently an employee of Astellas Pharma Europe Ltd. S Fu, N Hummel and I Czarny-Ozga are employees of Certara, which is a paid consultancy from Amicus Therapeutics, Ltd. T Mozaffar has advised for AbbVie, Alexion, Amicus Therapeutics, Inc., Annji, Argenx, Arvinas, Audentes, Cabaletta, Maze Therapeutics, Momenta, Ra Pharmaceuticals, Sanofi Genzyme, Sarepta, Spark Therapeutics and UCB; participates on the speaker's bureau for Sanofi Genzyme and the medical advisory boards for the Myositis Association, Neuromuscular Disease Foundation, Myasthenia Gravis Foundation of California and Myasthenia Gravis Foundation of America; has received research funding from the Myositis Association, the Muscular Dystrophy Association, the NIH and from the following sponsors: Alexion, Amicus Therapeutics, Inc., Annji, Argenx, Audentes, Bristol-Myers Squibb, Cabaletta, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi Genzyme, Spark Therapeutics, UCB and Valerion; is on the data safety monitoring board for Acceleron, Applied Therapeutics, Sarepta and the NIH. H Thom owns shares in Clifton Insight, a consulting company that has received fees from Amicus Therapeutics, Inc., Argenx, Bayer, Baxter, Daiichi-Sankyo, Eisai, Janssen, Lundbeck, Merck, Novartis, Novo Nordisk, Pfizer and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

Medical editing support was provided by Sophie Austin, PhD, at AMICULUM, Ltd, under the direction of the authors in accordance with Good Publication Practice guidelines and was funded by Amicus Therapeutics, Inc.

Secondary analysis disclosure

The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them, and that the use of these shared data is in accordance with the terms (if any) agreed upon their receipt. The data sources are fully referenced in the manuscript.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <https://creativecommons.org/licenses/by-nc-nd/4.0/>

References

Papers of special note have been highlighted as: ● of interest; ●● of considerable interest

1. Kishnani PS, Steiner RD, Bali D *et al.* Pompe disease diagnosis and management guideline. *Genet. Med.* 8(5), 267–288 (2006).
2. Schoser B, Roberts M, Byrne BJ *et al.* Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase III trial. *Lancet Neurol.* 20(12), 1027–1037 (2021).
- **This paper summarizes the results of the phase III PROPEL trial and shows that results on the primary and key secondary end points, 6MWD and FVC % predicted, respectively, were better in ERT-experienced patients.**
3. Huggins E, Holland M, Case LE *et al.* Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening. *Mol. Genet. Metab.* 135(3), 179–185 (2022).
4. Park KS. Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. *Mol. Genet. Metab. Rep.* 27, 100734 (2021).
5. van der Ploeg AT, Clemens PR, Corzo D *et al.* A randomized study of alglucosidase alfa in late-onset Pompe's disease. *N. Engl. J. Med.* 362(15), 1396–1406 (2010).
6. Food and Drug Administration. Nexvazyme™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761194s000lbl.pdf (2021).
7. European Medicines Agency. Nexviadyme, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf (2022).
8. European Medicines Agency. Pombiliti, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_en.pdf (2023).
9. European Medicines Agency. Opfolda, Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/opfolda-epar-product-information_en.pdf (2023).
10. Food and Drug Administration. Pombiliti™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761204s000lbl.pdf (2023).
11. Food and Drug Administration. Opfolda™, Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215211s000lbl.pdf (2023).
12. Singh A, Debnath R, Saini A *et al.* Cipaglucosidase alfa-atga: unveiling new horizons in Pompe disease therapy. *Health Sci. Rev.* 11, 100160 (2024).
13. Diaz-Manera J, Kishnani PS, Kushlaf H *et al.* Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a Phase III, randomised, multicentre trial. *Lancet Neurol.* 20(12), 1012–1026 (2021).
- **This paper summarizes the results of the phase III COMET trial and shows that, in enzyme replacement therapy (ERT)-naive patients, aval performs better than alglu on the primary and key secondary end points, forced vital capacity (FVC) % predicted and 6-minute walk distance (6MWD), respectively.**
14. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med. Decis. Making* 33(5), 607–617 (2013).
15. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat. Med.* 23(20), 3105–3124 (2004).
16. Phillippo DM, Ades AE, Dias S *et al.* Methods for population-adjusted indirect comparisons in health technology appraisal. *Med. Decis. Making.* 38(2), 200–211 (2018).
17. Mozaffar T, Schoser B, Kishnani P *et al.* Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02) (S48.007). *Neurology* 100(17 Suppl. 2), (2023).
18. Dimachkie MM, Barohn RJ, Byrne B *et al.* Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. *Neurology* 99(5), e536–e548 (2022).
- **This study presents long-term results on aval in ERT-naive (n = 10) and ERT-experienced (n = 14) patients from the NEO-1/-EXT trial.**
19. Signorovitch JE, Wu EQ, Yu AP *et al.* Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. *Pharmacoeconomics* 28(10), 935–945 (2010).
20. Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. *Pharmacoeconomics* 33(6), 537–549 (2015).
21. Phillippo DM, Dias S, Ades AE *et al.* Multilevel network meta-regression for population-adjusted treatment comparisons. *J. R. Stat. Soc. Ser. A Stat. Soc.* 183(3), 1189–1210 (2020).
- **This paper proposes a new indirect treatment comparison (ITC) method that is able to provide relative effect estimates for any target population of interest, not only for the population of the comparator trial and was applied in our study.**
22. Byrne BJ, Kishnani PS, Case LE *et al.* Pompe disease: design, methodology, and early findings from the Pompe Registry. *Mol. Genet. Metab.* 103(1), 1–11 (2011).

23. Semplicini C, De Antonio M, Taouagh N *et al.* Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry. *J. Inherit. Metab. Dis.* 43(6), 1219–1231 (2020).
24. Leahy J, Thom H, Jansen JP *et al.* Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: assessing the impact. *Stat. Med.* 38(14), 2505–2523 (2019).
- **This paper lays out how single-arm evidence can be incorporated into an network meta-analysis (NMA by matching the (aggregate) baseline characteristics of the single-arm trial to one of the comparator arms of the randomized trials already included in the network.**
25. Thom H, Leahy J, Jansen JP. Network meta-analysis on disconnected evidence networks when only aggregate data are available: modified methods to include disconnected trials and single-arm studies while minimizing bias. *Med. Decis. Making.* 42(7), 906–922 (2022).
26. Welton NJ, Phillippo DM, Owen R *et al.* CHTE2020 sources and synthesis of evidence; update to evidence synthesis methods. https://www.sheffield.ac.uk/sites/default/files/2022-02/CHTE-2020_Final_20April2020_Final.pdf (2020).
27. Page MJ, McKenzie JE, Bossuyt PM *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 372, n71 (2021).
28. Sterne JAC, Savović J, Page MJ *et al.* RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 366, l4898 (2019).
29. Sterne JAC, Hernán MA, Reeves BC *et al.* ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. *BMJ* 355, i4919 (2016).
30. Phillippo DM. multinma: Bayesian network meta-analysis of individual and aggregate data. <https://zenodo.org/record/6323335> (2022).
31. Stan Development Team. Stan modeling language users guide and reference manual, Version 2.33. <https://mc-stan.org> (2022).
32. R Core Team. R: a language and environment for statistical computing. <https://www.r-project.org/> (2019).
33. Phillippo DM. R package multinma. <https://cran.rstudio.com/web/packages/multinma/index.html> (2023).
34. Cabello JF, Marsden D. Pompe disease: clinical perspectives. *Orphan Drugs Res. Rev.* 7, 1–10 (2016).
35. Dornelles AD, Junges APP, Pereira TV *et al.* A systematic review and meta-analysis of enzyme replacement therapy in late-onset Pompe disease. *J. Clin. Med.* 10(21), 4828 (2021).
36. Papadimas GK, Anagnostopoulos C, Xirou S *et al.* Effect of long term enzyme replacement therapy in late onset Pompe disease: a single-centre experience. *Neuromuscul. Disord.* 31(2), 91–100 (2021).
37. Baek RC, Palmer R, Pomponio RJ *et al.* The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa. *Mol. Genet. Metab. Rep.* 8, 48–50 (2016).
38. American Statistical Association. American Statistical Association releases statement on statistical significance and p-values: provides principles to improve the conduct and interpretation of quantitative science. <https://www.amstat.org/asa/files/pdfs/p-valuestatement.pdf> (2016).
39. Sterne JAC, Davey Smith G. Sifting the evidence-what's wrong with significance tests? *BMJ* 322(7280), 226–231 (2001).
40. Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. *J. Clin. Epidemiol.* 68(1), 52–60 (2015).
- **This paper provides predictive distributions for particular disease areas and end points that were included as prior distributions into the random-effects (RE) models applied in our study.**
41. Hoaglin DC, Hawkins N, Jansen JP *et al.* Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health* 14(4), 429–437 (2011).
42. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. *J. R. Stat. Soc.* 64(4), 583–639 (2002).
43. Haeussler K, Wang X, Winfree KB *et al.* Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. *Future Oncol.* 18(16), 2007–2028 (2022).
44. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J. Clin. Epidemiol.* 64(2), 163–171 (2011).
45. van der Ploeg AT, Barohn R, Carlson L *et al.* Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. *Mol. Genet. Metab.* 107(3), 456–461 (2012).
46. van der Ploeg A, Carlier PG, Carlier R-Y *et al.* Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study. *Mol. Genet. Metab.* 119(1–2), 115–123 (2016).
47. Sarah B, Giovanna B, Emanuela K *et al.* Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. *J. Neurol.* 269(2), 733–741 (2022).
48. Schoser B, Stewart A, Kanters S *et al.* Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. *J. Neurol.* 264(4), 621–630 (2017).
49. Byrne BJ, Schoser B, Kishnani PS *et al.* Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02). *J. Neurol.* 271(4), 1787–1801. (2024).

50. Kishnani PS, Diaz-Manera J, Kushlaf H *et al.* Efficacy and safety of avalglucosidase alfa in participants with late-onset pompe disease after 145 weeks' treatment during the COMET trial. *19th Annual WORLDSymposium™*. Orlando, FL, USA (22–26 February 2023).
- **This study presents open-label extension (OLE) results until Week 145 of the COMET trial and provides the second source of evidence on the effect of aval in ERT-experienced patients with late-onset Pompe disease (LOPD) (those who switched from alglu to aval after 49 weeks of treatment).**
51. Mozaffar T, Byrne BJ, Diaz-Manera J *et al.* Long-term efficacy and safety of cipaglucosidase alfa/miglustat in patients with Pompe disease: a phase III open-label extension study (ATB200-07). *MDA Clinical & Scientific Conference*. Dallas, TX, USA (19–22 March 2023).
52. Brudvig JJ, Tuske S, Castelli J, Weimer JM. Comments on: increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice. *J. Pharmacol. Exp. Ther.* 389(3), 310–312 (2024).
53. George K, Anding A. Response to Comments on “Increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice”. *J. Pharmacol. Exp. Ther.* 389(3), 313–314 (2024).
54. Selvan N, Mehta N, Venkateswaran S *et al.* Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase. *J. Biol. Chem.* 296, 100769 (2021).
55. Pena LDM, Barohn RJ, Byrne BJ *et al.* Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase I, open-label, multicenter, multinational, ascending dose study. *Neuromuscul. Disord.* 29(3), 167–186 (2019).
56. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.* 14(1), 135 (2014).
57. Schoser B, Kishnani P, Bratkovic D *et al.* FP17 Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label phase I/II study (ATB200-02). *Neuromuscul. Disord.* 32, S73 (2022).
58. Raza S, Keyzor I, Shohet S *et al.* POSA283 Differential appraisal of functional outcome measures by health technology assessment (HTA) agencies when reviewing therapies for rare muscular, skeletal and neurodegenerative disorders. *Value Health.* 25(1), S175 (2022).
59. Roberts M, Proskorovsky I, Guyot P *et al.* Late-onset Pompe disease patients treated with avalglucosidase alfa show favorable results compared with cipaglucosidase alfa plus miglustat: indirect treatment comparison. *19th Annual WORLDSymposium™*. Orlando, FL, USA (22–26 February 2023).